Adverse drug reactions associated with antiretroviral therapy during pregnancy

Bibliography

• UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. World Health Organization; United States: 2013
   Google Scholar
• Bryson YJ. Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS 1996;10(Suppl 3):S33-42
   PubMedGoogle Scholar
• Mofenson LM. Mother-child HIV-1 transmission. Obstet Gynecol Clin North Am 1997;24:75-84
   Web of Science ®Google Scholar
• Nielsen K, João Filho EC, Grinsztejn B, et al. Effect of Antiretroviral treatment on the reduction of perinatal HIV transmission in Brazil [abstract 23607]. XII World Aids Conference, Geneva, Switzerland; 1998
   Google Scholar
• Rubini N, Arabe J, Leal DWC, et al. Main difficulties in the reduction of HIV vertical transmission in Rio de Janeiro, Brazil [abstract 23311]. From Program and Abstracts of the 12th World Aids Conference, Geneva, Switzerland; June-July 1998
   Google Scholar
• Mussi-Pinhata MM, Kato CM, Duarte G, et al. Factors associated with vertical HIV transmission during two different time periods: the impact of zidovudine use on clinical practice at a Brazilian reference centre. Int J STD AIDS 2003;14:818-25
   PubMed Web of Science ®Google Scholar
• Mofenson LM. Mother-child HIV-1 transmission: timing and determinants. Obstet Gynecol Clin North Am 1997;24:759-84
   PubMed Web of Science ®Google Scholar
• Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992;340:582-8
   PubMedGoogle Scholar
• Datta P, Embree JE, Kreiss JK, et al. Mother-to∼child transmission of Human Immunodeficiency Virus type 1: report from the Nairobi Study. J Infect Dis 1994;170:1134-40
   PubMed Web of Science ®Google Scholar
• Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000;283:1167-74
   PubMed Web of Science ®Google Scholar
• Fawzi W, Msamanga G, Renjifo B, et al. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS 2001;15:1157-65
   PubMed Web of Science ®Google Scholar
• Newell ML. Vertical transmission of HIV-1 infection. Trans R Soc Trop Med Hyg 2000;94:1-2
   PubMed Web of Science ®Google Scholar
• Wabwire-Mangen F, Gray RH, Mmiro FA, et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr 1999;22:379-85
   PubMed Web of Science ®Google Scholar
• Taha TE, Gray RH. Genital tract infections and perinatal transmission of HIV. Ann N Y Acad Sci 2000;918:84-98
   PubMed Web of Science ®Google Scholar
• Van Dyke RB, Korber BT, Popek E, Koopmans PP. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999;179:319-28
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280:55-60
   PubMed Web of Science ®Google Scholar
• The European Mode of Delivery Collaboration. Elective caesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353:1035-9
   PubMed Web of Science ®Google Scholar
• The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87
   PubMed Web of Science ®Google Scholar
• Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9
   PubMed Web of Science ®Google Scholar
• Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1. French Perinatal Cohort Studies. SEROGEST Cohort Group. J Infect Dis 1997;175:172-5
   PubMed Web of Science ®Google Scholar
• Garcia PM, Kalish LA, Pitt J, et al. RNA and transmission: maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study (WITS). N Engl J Med 1999;341:394-402
   PubMed Web of Science ®Google Scholar
• The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999;3:1377-85
   Google Scholar
• Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999;353:773-80
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 2001;183:539-45
   PubMed Web of Science ®Google Scholar
• Read JS, Newell ML. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005;4:CD005479
   PubMedGoogle Scholar
• Leroy V, Newell ML, Dabis F, et al. International multicenter pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. Lancet 1998;352:597-600
   PubMed Web of Science ®Google Scholar
• Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of HIV-1. J Infect Dis 2003;187:725-35
   PubMed Web of Science ®Google Scholar
• Phadke MA, Bulakh PM, Kshirsagar NA. Nevirapine to prevent HIV transmission via breastfeeding. Lancet 2008;372:287-91
   PubMed Web of Science ®Google Scholar
• Coll Hernandez M, Boucher CA, Fortuny C, et al. Vertical HIV-1 transmission correlated with a high maternal viral load at delivery. JAIDS 1997;14:26-30
   Google Scholar
• Katz IT, Shapiro R, Li D, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr 2010;54:27-34
   PubMed Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of Human Immunodeficiency Virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80
   PubMed Web of Science ®Google Scholar
• CDC (Centers for Disease Control and Prevention). Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission –Thailand, 1996-1998. MMWR Morb Mortal Wkly Rep 1998;47:151-4
   PubMedGoogle Scholar
• Dabis F, Msellati P, Meda N, et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV-1 in breastfed children in Cote d’ Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999;353:786-92
   PubMed Web of Science ®Google Scholar
• Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother to child transmission of HIV-1 in Kampala, Uganda: HIV-1NET 012 randomised trial. Lancet 1999;354:795-802
   PubMed Web of Science ®Google Scholar
• Shaffer N, Roongpitsuthipong A, Siriwaisn W, et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission. Thailand. J Infect Dis 1999;179:590-9
   PubMed Web of Science ®Google Scholar
• Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV-1 Prevention Trial (Thailand) Investigators. N Engl J Med 2000;343:982-91
   PubMed Web of Science ®Google Scholar
• Petra Study Team. Efficacy of three short course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised double-blind, placebo-controlled trial. Lancet 2002;359:1178-86
   PubMed Web of Science ®Google Scholar
• Gandhi M, Mwesigwa J, Aweeka F, et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr 2013;63(5):578-84
   PubMed Web of Science ®Google Scholar
• Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 2005;19:1289-97
   PubMed Web of Science ®Google Scholar
• Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006;296:794-805
   PubMed Web of Science ®Google Scholar
• Fowler MG, Lampe MA, Jamieson DJ, et al. Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions. Am J Obstet Gynecol 2007;197:S3-9
   PubMed Web of Science ®Google Scholar
• Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14
   PubMed Web of Science ®Google Scholar
• Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012;366:2368-79
   PubMed Web of Science ®Google Scholar
• João EC, Cruz ML, Menezes JA, et al. Vertical transmission of HIV in Rio de Janeiro. Brazil. AIDS 2003;17:1853-5
   PubMed Web of Science ®Google Scholar
• <conf-loc>Shapiro D, Tuomala R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery and viral load in 2895 US women (PACTG 367) [Oral abstract]. 11th CROI. San Francisco-CA; EUA. 2004
   Google Scholar
• Kreitchmann R, Fuchs SC, Suffert T, Preussler G. Perinatal HIV-1 transmission among low income women participants in the HIV/AIDS Control Program in Southern Brazil: a cohort study. BJOG 2004;111:579-84
   PubMed Web of Science ®Google Scholar
• Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010(3):CD008440
   Google Scholar
• Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. Aids Rev 2011;13:198-213
   PubMed Web of Science ®Google Scholar
• Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in botswana. N Engl J Med 2010;362:2282-94
   PubMed Web of Science ®Google Scholar
• The Kesho Bora Study Group. Maternal HIV-1 Disease Progression 18-24 Months Post-Delivery According to Antiretroviral Prophylaxis Regimen (Triple-Antiretroviral Prophylaxis during Pregnancy and Breastfeeding Versus Zidovudine/Single-Dose Nevirapine Prophylaxis): the Kesho Bora Randomized Controlled Trial. Clin Infect Dis 2012;55:449-60
   PubMed Web of Science ®Google Scholar
• Azria E, Moutafoff C, Schmitz T, et al. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antivir Ther 2009;14(3):423-32
   PubMed Web of Science ®Google Scholar
• Peixoto MF, Pilotto JH, Stoszek SK, et al. Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities. Braz J Infect Dis 2011;15:253-61
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007;21:2409-15
   PubMed Web of Science ®Google Scholar
• Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med 2011;12:570-9
   PubMed Web of Science ®Google Scholar
• Navér L, Albert J, Belfrage E, et al. Prophylaxis and treatment of HIV-1 infection in pregnancy: swedish recommendations 2010. Scand J Infect Dis 2011;43:411-23
   PubMed Web of Science ®Google Scholar
• Santini-Oliveira M, Estrela Rde C, Veloso VG, et al. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother 2014;58:2884-93
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505
   PubMed Web of Science ®Google Scholar
• World Health Organization 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. Available from: www.who.int/hiv/pub/guidelines/arv2013/en/ [Accessed on 16 July 2014]
   Google Scholar
• Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Sex differences in zidovudine and lamivudine triphosphate concentrations in HIV-infected patients. AIDS 2003;17(15):2159-68
   PubMed Web of Science ®Google Scholar
• Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetic and therapeutic drug monitoring of antiretrovirals in pregnant women. BJCP 2008;66:179-95
   Web of Science ®Google Scholar
• Knoppert D. Safety and efficacy of drugs in pregnancy. J Popul Ther Clin Pharmacol 2011;18(3):e506-12
   PubMedGoogle Scholar
• Colbers A, Greupink R, Burger D. Pharmacological considerations on the use of antiretrovirals in pregnancy. Curr Opin Infect Dis 2013;26:575-88
   PubMed Web of Science ®Google Scholar
• Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann NY Acad Sci 2000;918:287-97
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis 2002;21:835-8
   Google Scholar
• Santini-Oliveira M, Friedman RK, Veloso VG, et al. Incidence of antiretroviral adverse drug reactions in pregnant women in two referral centers for HIV prevention of mother-to-child-transmission care and research in Rio de Janeiro. Brazil. Braz J Infect Dis 2014;18:372-8
   PubMed Web of Science ®Google Scholar
• Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002;78:58-9
   PubMed Web of Science ®Google Scholar
• CDC (Centers for Disease Control and Prevention). Recommendations for use of antiretroviral drugs in pregnant HIV infected women for maternal health and interventions to reduce perinatal transmission in the United States. 2004
   Google Scholar
• Foster C, Lyall H, Olmscheid B, et al. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med 2009;10:397-406
   PubMed Web of Science ®Google Scholar
• Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006;7:255-60
   PubMed Web of Science ®Google Scholar
• Kondo W, Carraro EA, Prandel E, et al. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. Braz J Infect Dis 2007;11:544-8
   PubMed Web of Science ®Google Scholar
• Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007;8:357-66
   PubMed Web of Science ®Google Scholar
• Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007;44:371-6
   PubMed Web of Science ®Google Scholar
• Aaron E, Kempf MC, Criniti S, et al. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLoS One 2010;5:e12617
   PubMed Web of Science ®Google Scholar
• Bera E, Mia R. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis. S Afr Med J 2012;102:855-9
   PubMed Web of Science ®Google Scholar
• Ford N, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS 2013;27:1135-43
   PubMed Web of Science ®Google Scholar
• Eshelman SH, Mracna M, Guay LA, et al. Selection of fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-7
   PubMed Web of Science ®Google Scholar
• Chaix ML, Ekouevi DK, Peytavin G, et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother 2007;51(3):896-901
   PubMed Web of Science ®Google Scholar
• Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:35-47
   Web of Science ®Google Scholar
• Giaquinto C, Rampon O, De Rossi A. Antiretroviral therapy for prevention of mother-to-child HIV transmission: focus on single-dose nevirapine. Clin Drug Investig 2006;26:611-27
   PubMed Web of Science ®Google Scholar
• Ellis GM, Huang S, Hitti J, Frenkel LM; P1022 Study Team. Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. J Acquir Immune Defic Syndr 2011;58:241-7
   PubMed Web of Science ®Google Scholar
• Chersich MF, Urban MF, Venter FW, et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006;3:11-16
   PubMedGoogle Scholar
• Tubiana R, Mandelbrot L, Delmas S, et al. LPV/r Monotherapy during pregnancy for PMTCT of HIV-1: The PRIMEVA/ANRS 135 Randomized Trial, pregnancy outcomes. Paper # 125LB 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011
   Google Scholar
• Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006;20:1931-9
   PubMed Web of Science ®Google Scholar
• Bonafe SM, Costa DA, Vaz MJ, et al. A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancy. AIDS Patient Care STDS 2013;27:589-95
   PubMed Web of Science ®Google Scholar
• Cressey TR, Jourdain G, Rawangban B, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010;24:2193-200
   PubMed Web of Science ®Google Scholar
• Else LJ, Douglas M, Dickinson L, et al. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother 2012;56(2):816-24
   PubMed Web of Science ®Google Scholar
• Lambert JS, Else LJ, Jackson V, et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med 2011;12:166-73
   PubMed Web of Science ®Google Scholar
• Best BM, Stek AM, Mirochnik M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010;54(4):381-8
   PubMed Web of Science ®Google Scholar
• Patterson KB, Diamond JB, Prince HA, et al. Pharmacokinetics of the lopinavir/ritonavir tablet in HIV-infected pregnant women: a longitudinal investigation of protein bound and unbound drug exposure with empiric dosage adjustment. 18th CROI, Boston-MA, EUA; 2011. Paper #645
   Google Scholar
• Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002;360:1152-4
   PubMed Web of Science ®Google Scholar
• Mawson AR. Effects of antiretroviral therapy on occurrence of pre-eclampsia. Lancet 2003;361:347-8
   PubMed Web of Science ®Google Scholar
• Frank KA, Buchmann EJ, Schackis RC. Does human immunodeficiency virus infection protect against pre-eclampsia-eclampsia? Obstet Gynecol 2004;104(2):238-42
   PubMed Web of Science ®Google Scholar
• Mattar R, Amed AM, Lindsey PC, et al. Pre-eclampsia and HIV infection. Eur J Obstet Gynecol Reprod Biol 2004;117:240-1
   PubMed Web of Science ®Google Scholar
• Haeri S, Shauer M, Dale M, et al. Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol 2009;201:e311-15
   PubMed Web of Science ®Google Scholar
• Boyajian T, Shah PS, Murphy KE. Risk of pre-eclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. J Obstet Gynaecol Can 2012;34:136-41
   PubMedGoogle Scholar
• Machado ES, Krauss MR, Megazzini K, et al. Hypertension, preeclampsia and eclampsia among HIV-infected pregnant women from Latin America and Caribbean countries. J Infect 2014;68:572-80
   PubMed Web of Science ®Google Scholar
• Chougrani I, Luton D, Matheron S, et al. Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl) 2013;5:253-62
   PubMedGoogle Scholar
• Watts DH, Balasubramanian R, Maupin RT Jr, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004;190:506-16
   PubMed Web of Science ®Google Scholar
• El Beitune P, Duarte G, Foss MC, et al. Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women. Diabetes Metab Res Rev 2006;22(1):59-63
   PubMed Web of Science ®Google Scholar
• Gonzalez-Tome MI, Ramos Amador JT, Guillen S, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med 2008;9:868-74
   PubMed Web of Science ®Google Scholar
• Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007;196:e331-3
   PubMed Web of Science ®Google Scholar
• Tang JH, Sheffield JS, Grimes J, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006;107:1115-19
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007;21:607-1
   PubMed Web of Science ®Google Scholar
• Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004;18:2337-9
   PubMed Web of Science ®Google Scholar
• Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006;193:1195-201
   PubMed Web of Science ®Google Scholar
• Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008;9:6-13
   PubMed Web of Science ®Google Scholar
• Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d’Ivoire. AIDS 2008;22:1815-20
   PubMed Web of Science ®Google Scholar
• Ravizza M, Martinelli P, Bucceri A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007;195:913-14
   PubMed Web of Science ®Google Scholar
• Sibiude J, Warszawski J, Tubiana R, et al. ANRS CO1/CO11 Large increase in prematurity between 1990 and 2009 in HIV-infected women in the national ANRS French Perinatal Cohort: does ritonavir boost play a role? [abstract 743]. 18th Conference on Retroviruses and Opportunistic Infections; Feb 27-Mar 2, 2011; Boston, MA
   Google Scholar
• Patel K, Shapiro DE, Brogly SB, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010;201:1035-44
   PubMed Web of Science ®Google Scholar
• Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006;20:2345-53
   PubMed Web of Science ®Google Scholar
• Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note of caution. J Infect Dis 2012;206:1639-41
   PubMed Web of Science ®Google Scholar
• Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007;21:1019-26
   PubMed Web of Science ®Google Scholar
• Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012;206:1695-705
   PubMed Web of Science ®Google Scholar
• Parekh N, Ribaudo H, Souda S, et al. Risk factors for very preterm delivery and delivery of very-small-for-gestational-age infants among HIV-exposed and HIV-unexposed infants in Botswana. Int J Gynaecol Obstet 2011;115:20-5
   PubMed Web of Science ®Google Scholar
• Watts DH, Williams PL, Kacanek D, et al. Combination antiretroviral use and preterm birth. J Infect Dis 2013;207:612-21
   PubMed Web of Science ®Google Scholar
• Dola CP, Khan R, DeNicola N, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med 2011;40:51-5
   PubMed Web of Science ®Google Scholar
• Briand N, Mandelbrot L, Le Chenadec J, et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 2009;23:1235-43
   PubMed Web of Science ®Google Scholar
• Ivanovic J, Nicastri E, Anceschi MM, et al. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res 2009;7:620-5
   PubMed Web of Science ®Google Scholar
• Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994;169:1100-2
   PubMed Web of Science ®Google Scholar
• Rondinini C, Venerosi A, Branchi I, et al. Long-term effects of prenatal 3’-azido-3’-deoxythymidine (AZT) exposure on intermale aggressive behaviour of mice. Psychopharmacology (Berl) 1999;145:317-23
   PubMed Web of Science ®Google Scholar
• Fujinaga M, Schulte M, Holodniy M. Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system. Teratology 2000;62:108-14
   PubMedGoogle Scholar
• Venerosi A, Valanzano A, Alleva E, Calamandrei G. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice. Teratology 2001;63:26-37
   PubMedGoogle Scholar
• Calamandrei G, Valanzano A, Puopolo M, Aloe L. Developmental exposure to the antiretroviral drug zidovudine increases brain levels of brain-derived neurotrophic factor in mice. Neurosci Lett 2002;333:111-14
   PubMed Web of Science ®Google Scholar
• Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 2002;29:323-9
   PubMed Web of Science ®Google Scholar
• Bishop J B, Tani Y, Witt K, et al. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol Sci 2004;81:512-17
   PubMed Web of Science ®Google Scholar
• Thorne C, Newell ML. Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues. Med Wieku Rozwoj 2003;7:425-36
   PubMedGoogle Scholar
• Poirier MC, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003;33:175-83
   PubMed Web of Science ®Google Scholar
• Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004;114:598-603
   PubMed Web of Science ®Google Scholar
• Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics 2006;118:e1071-7
   PubMed Web of Science ®Google Scholar
• Bulterys M, Nesheim S, Abrams EJ, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci 2000;918:212-21
   PubMed Web of Science ®Google Scholar
• Dominguez K, Bertolli J, Fowler M, et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD). USA. Ann N Y Acad Sci 2000;918:236-46
   PubMed Web of Science ®Google Scholar
• Lindegren ML, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000;918:222-35
   PubMed Web of Science ®Google Scholar
• Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics 2006;118:1139-45
   PubMed Web of Science ®Google Scholar
• Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. Jama 1999;281:151-7
   PubMed Web of Science ®Google Scholar
• Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003;17:2053-61
   PubMed Web of Science ®Google Scholar
• Feiterna-Sperling C, Weizsaecker K, Buhrer C, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune Defic Syndr 2007;45:43-51
   PubMed Web of Science ®Google Scholar
• European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:380-7
   PubMed Web of Science ®Google Scholar
• El Beitune P. Duarte G. Antiretroviral agents during pregnancy: consequences on hematologic parameters in HIV-exposed, uninfected newborn infant. Eur J Obstet Gynecol Reprod Biol 2006;128:59-63
   PubMed Web of Science ®Google Scholar
• Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005;94:1571-7
   PubMed Web of Science ®Google Scholar
• Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study. J Infect Dis 2006;194:1089-97
   PubMed Web of Science ®Google Scholar
• Heidari S, Mofenson L, Cotton MF, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011;57:290-6
   PubMed Web of Science ®Google Scholar
• Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011;306:70-8
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Mazy F, Floch-Tudal C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol 2011;157:18-21
   PubMed Web of Science ®Google Scholar
• Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 2002;29:323-9
   PubMed Web of Science ®Google Scholar
• Olivero OA. Relevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy. Mutat Res 2008;658:184-90
   PubMed Web of Science ®Google Scholar
• National Study of HIV in Pregnancy and Childhood (NSHPC). NSHPC update. 2012. Available from: www.nshpc.ucl.ac.uk/ [ [Acessed on 5th June 2014]
   Google Scholar
• Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Register International Interim Report for 1 January 1989 through 31 January 2013. 25 (1) ed Registry Coordinating Center; Wilmington, NC, USA: 2013
   Google Scholar
• Nightingale SL. From the Food and Drug Administration. JAMA 1998;280:1472
   PubMedGoogle Scholar
• De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002;162:355
   PubMed Web of Science ®Google Scholar
• British HIV Association. Guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012;13(Suppl 2):87-157
   PubMed Web of Science ®Google Scholar
• Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2014;28:S123-31
   PubMed Web of Science ®Google Scholar
• Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. United states department of health and human services panel on treatment of hiv-infected pregnant women and prevention of perinatal transmission, Washington, DC; 2012. Available from: http:/aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf [Accessed 15 June 2013]
   Google Scholar
• World Health Organization. Use of efavirenz during pregnancy: a public health perspective. Technical update on treatment optimization. World Health Organization, Geneva; 2012. Available from: www.who.int/hiv/pub/treatment2/efavirenz/en [Accessed 15 May 2014]
   Google Scholar
• Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009;23(3):434-5
   PubMed Web of Science ®Google Scholar
• Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 2010;15:677-80
   PubMed Web of Science ®Google Scholar
• Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med 2011;12:257-8
   PubMed Web of Science ®Google Scholar
• Weizsaecker K, Kurowski M, Hoffmeister B, et al. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS 2011;22:294-5
   PubMed Web of Science ®Google Scholar
• Taylor N, Touzeau V, Geit M, et al. Raltegravir in pregnancy: a case series presentation. Int J STD AIDS 2011;22:358-60
   PubMed Web of Science ®Google Scholar
• Vigano A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011;16:1259-66
   PubMed Web of Science ®Google Scholar
• Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012;26:1151-9
   PubMed Web of Science ®Google Scholar
• Martorell C, Theroux E, Bermudez A, et al. Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women. Pediatr Infect Dis J 2010;29:985
   PubMed Web of Science ®Google Scholar
• Cespedes MS, Castor D, Ford SL, et al. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquir Immune Defic Syndr 2013;62:550-4
   PubMed Web of Science ®Google Scholar
• Zorrilla CD, Wright R, Osiyemi OO, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med 2014;15:50-6
   PubMed Web of Science ®Google Scholar
• Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0 [Accessed 5 June 2014] Last updated: March 28, 2014; last reviewed: March 28, 2014
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Accessed 5 June 2014]
   Google Scholar